

Immunomodulators

Last Updated: February 29, 2024

Summary Recommendations
<ul style="list-style-type: none">• The hyperactive inflammatory response to SARS-CoV-2 infection plays a central role in the pathogenesis of COVID-19. See Therapeutic Management of Hospitalized Adults With COVID-19 and Therapeutic Management of Hospitalized Children With COVID-19 for the COVID-19 Treatment Guidelines Panel's (the Panel) recommendations on the use of the following immunomodulators in hospitalized patients with COVID-19 according to their disease severity (listed in alphabetical order):<ul style="list-style-type: none">• Abatacept• Baricitinib (or tofacitinib)• Dexamethasone• Infliximab• Tocilizumab (or sarilumab)• There is insufficient evidence for the Panel to recommend either for or against the use of the following immunomodulators for the treatment of COVID-19:<ul style="list-style-type: none">• Anakinra• Inhaled corticosteroids• Vilobelimab• The Panel recommends against the use of canakinumab for the treatment of COVID-19, except in a clinical trial (BIIa).
Each recommendation in the Guidelines receives a rating for the strength of the recommendation (A, B, or C) and a rating for the evidence that supports it (I, IIa, IIb, or III). See Guidelines Development for more information.